AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings on Breztri Aerosphere for Uncontrolled Asthma

Shots:

• The P-III (LOGOS & KALOS) trials evaluated Breztri Aerosphere (BGF; 320/28.8/9.6μg or 320/14.4/9.6μg) vs PT009 (ICS/LABA via Aerosphere) & Symbicort pressurized metered-dose inhaler (pMDI) in pts with uncontrolled asthma; Regulatory filings in asthma are under review in all major regions
• In pooled analysis, Breztri improved lung function by 76 mL in morning pre-dose trough FEV1 & 90 mL in FEV1 AUC0–3 over 24wks., & reduced the annualized rate of severe asthma exacerbations in pts with or without recent exacerbations; full results were published in The Lancet Respiratory Medicine
• Breztri Aerosphere is a single-inhaler triple therapy combination of formoterol (LABA), glycopyrronium (LAMA), & budesonide (ICS), delivered via Aerosphere pMDI

Ref: AstraZeneca  | Image: AstraZeneca | Press Release

Related News: Daiichi Sankyo and AstraZeneca Report the US FDA Priority Review for Datroway to Treat Metastatic Triple Negative Breast Cancer

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com